Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-09-04

IQVIA HOLDINGS INC. (IQV)

CEO Ari Bousbib was paid $28,128,245 in fiscal year 2025, ↑ up 5.2% from fiscal year 2024, the 72nd percentile of its disclosed peer group (SEC filing 0001628280-26-012892 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$28,128,245 ↑
Ari Bousbib total, FY2025
72nd
CEO pay percentile vs peers
275:1
CEO-to-median pay ratio
80.11%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

IQV's next annual pay disclosure, estimated February 26, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Ari Bousbib$1,800,000$0$15,749,957$4,528,317$4,966,127$689,848$393,996$28,128,245
Chairman and Chief Executive Officer
Ronald Bruehlman905,00006,749,8072,249,9841,294,584177,82567,00011,444,200
Executive Vice President, Chief Financial Officer
Alistair Grenfell629,90705,999,9641,999,950806,9450267,7409,704,506
President, Commercial Solutions
W. Richard Staub III800,00005,249,9181,749,982943,014086,0658,828,979
President, Research & Development Solutions
Eric Sherbet665,00002,999,982999,946764,301071,5695,500,798
Executive Vice President, General Counsel and Secretary

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Ari Bousbib$28,128,245$26,732,998$29,151,752↑ +1,395,247
Ronald Bruehlman11,444,2008,370,4358,564,048↑ +3,073,765
Alistair Grenfell9,704,506———
W. Richard Staub III8,828,97910,744,1131,927,926↓ −1,915,134
Eric Sherbet5,500,7984,173,8223,973,148↑ +1,326,976

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read IQVIA HOLDINGS INC.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper IQV reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the IQVIA HOLDINGS INC. Peer Teardown Report

$28,128,245 Ari Bousbib total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of September 4, 2026 · Source: 0001628280-26-012892 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for IQV

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
IQVon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order IQV

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against IQV
16 companies name IQV as a compensation peer

The list of companies that name IQV as a peer is temporarily unavailable — recheck shortly.

Get the IQVIA HOLDINGS INC. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Ari BousbibCEO$28,128,245
Eric SherbetGeneral Counsel$5,500,798
Alistair GrenfellEVP$9,704,506
Ronald BruehlmanCFO$11,444,200
W. Richard Staub IIIEVP$8,828,979
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Carol J. BurtIndependent Director$385,508
Colleen A. GogginsIndependent Director$383,008
James A. FasanoIndependent Director$390,508
John G. DanhaklIndependent Director$363,008
John M. Leonard, M.DLead Independent Director$418,008
John P. ConnaughtonFormer director (through FY2025)$27,500
Leslie Wims MorrisIndependent Director$353,008
Sheila A. StampsIndependent Director$358,008
Todd B. SisitskyIndependent Director—
William G. Kaelin Jr., M.DIndependent Director$28,125
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Carol J. BurtDirector2026-04-23A1,571$0$0CommonForm 4 ↗
John G. DanhaklDirector2026-04-23A1,57100CommonForm 4 ↗
John M. LeonardDirector2026-04-23A1,57100CommonForm 4 ↗
Morris Leslie WimsDirector2026-04-23A1,571161252,428Derivative, Class A CommonForm 4 ↗
Sheila A. StampsDirector2026-04-23A1,571161252,428Derivative, Class A CommonForm 4 ↗
Colleen A. GogginsDirector2026-04-23A1,57100CommonForm 4 ↗
James A. FasanoDirector2026-04-23A1,571161252,428Derivative, Class A CommonForm 4 ↗
William G. Kaelin JrDirector2026-04-23A1,571161252,428Derivative, Class A CommonForm 4 ↗
John G. DanhaklDirector2026-05-07A18517933,048Derivative, Class A CommonForm 4 ↗
James A. FasanoDirector2026-05-07A22817940,730Derivative, Class A CommonForm 4 ↗
Colleen A. GogginsDirector2026-05-07A21417938,229Derivative, Class A CommonForm 4 ↗
Morris Leslie WimsDirector2026-05-07A17117930,547Derivative, Class A CommonForm 4 ↗
John G. DanhaklDirector2026-07-14A16020833,253Derivative, Class A CommonForm 4 ↗
James A. FasanoDirector2026-07-14A19520840,527Derivative, Class A CommonForm 4 ↗
Colleen A. GogginsDirector2026-07-14A18320838,033Derivative, Class A CommonForm 4 ↗
Morris Leslie WimsDirector2026-07-14A14820830,759Derivative, Class A CommonForm 4 ↗
Ari BousbibDirector2026-07-29D156,2067812,216,871Derivative, Class A CommonForm 4 ↗
Ari BousbibDirector2026-07-29D53,19124513,020,093CommonForm 4 ↗
Ari BousbibDirector2026-07-29D44,03924610,837,117CommonForm 4 ↗
Ari BousbibDirector2026-07-29D4,5842471,131,560CommonForm 4 ↗
Ari BousbibDirector2026-07-29D4,4652471,103,302CommonForm 4 ↗
Ari BousbibDirector2026-07-29A156,2067812,216,871CommonForm 4 ↗
Eric SherbetSee Remarks2026-07-29D5,0002491,245,800CommonForm 4 ↗
Ari BousbibDirector2026-07-29D2,069247511,043CommonForm 4 ↗
Ari BousbibDirector2026-07-29D47,85824511,706,067CommonForm 4 ↗
Keriann CherofskySee Remarks2026-07-29D558245136,827CommonForm 4 ↗
Bhavik PatelSee Remarks2026-07-31D1,855235436,426CommonForm 4 ↗
W. Richard Staub IIISee Remarks2026-08-03D5,5002331,279,740CommonForm 4 ↗
James G. BerkshireSee Remarks2026-09-02D2,713262709,558CommonForm 4 ↗
James G. BerkshireSee Remarks2026-09-02A5,381132709,323CommonForm 4 ↗
James G. BerkshireSee Remarks2026-09-02D2,668261697,228CommonForm 4 ↗
James G. BerkshireSee Remarks2026-09-02D5,381132709,323Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
W. Richard Staub III—2025-01-28——12,903—$5,249,918
Alistair Grenfell—2025-01-28——14,747—5,999,964
Ari Bousbib—2025-01-28——38,711—15,749,957
Ari Bousbib—2025-01-28——77,422—4,528,317
Ronald Bruehlman—2025-01-28——33,180—2,249,984
W. Richard Staub III—2025-01-28——25,807—1,749,982
Alistair Grenfell—2025-01-28————1,999,950
Eric Sherbet—2025-01-28——7,373—2,999,982
Eric Sherbet—2025-01-28————999,946
Alistair GrenfellPSU2025-01-2814,74729,494—58,988—
Ronald Bruehlman—2025-01-28——16,590—6,749,807
03b

Vehicle mix — grant-date fair value by award type

Grant-level vehicle detail not disclosed.

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Ronald BruehlmanSAR6,867232.11—
Ari BousbibSAR24,034232.11—
Ronald BruehlmanSAR31,603203.43—
Alistair GrenfellPSU17,495—3,943,548
W. Richard Staub IIISAR24,580203.43—
Eric SherbetSAR6,331214.34—
Alistair GrenfellSAR3,434232.11—
Ari BousbibSAR48,345214.34—
Ari BousbibSAR73,741203.43—
W. Richard Staub IIISAR1,145232.11—
Alistair GrenfellSAR11,511214.34—
Alistair GrenfellSAR28,091203.43—
Eric SherbetSAR2,861232.11—
W. Richard Staub IIIPSU25,807—5,817,156
Ari BousbibPSU77,422—17,451,693
W. Richard Staub IIIPSU21,702—4,891,848
Ari BousbibPSU73,481—16,563,352
Ronald BruehlmanPSU33,180—7,479,104
Alistair GrenfellPSU29,494—6,648,243
Ronald BruehlmanPSU20,994—4,732,258
Eric SherbetPSU14,747—3,324,121
W. Richard Staub IIIPSU13,996—3,154,838
Eric SherbetPSU9,622—2,168,895
Ronald BruehlmanSAR13,813214.34—
W. Richard Staub IIISAR9,208214.34—
Eric SherbetSAR14,045203.43—
05

Incentive-plan design — the Compensation Discussion & Analysis

Our compensation philosophy continues to focus on creating an alignment between executive compensation and business performance by rewarding our named executive officers for achieving financial, strategic, operational, leadership and governance goals that are intended to contribute to long-term stockholder value.

CEO STI target (% of salary)200%
CEO LTI target (% of salary)—
Independent consultantMeridian Compensation Partners, LLC
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-04-23118,398,35529,398,856430,76580.11%Passed
20252025-04-24125,637,76926,212,786539,57682.74%Passed
20242024-04-16134,057,26326,075,678379,39083.72%Passed
20232023-04-18126,672,48332,526,896105,93479.57%Passed
20222022-04-12119,792,32637,774,0701,521,37676.03%Passed
20202020-04-0676,054,31288,997,130211,09746.08%Failed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-04-2380.11%a
20252025-04-2482.74%b
20242024-04-1683.72%c

a. Approved under the standard stated in the filing — “Proposal Board Recommendation Vote Required Effect of Abstentions and Broker Non-Votes 1 Election of director nominees to serve for the next year and until their successors are elected and qualified FOR each nominee Majority of votes cast No effect 2 Advisory (non-binding) vote to approve our executive compensation (say-on-pay) FOR Not Applicable (1) No effect 3 Ratification of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 FOR Majority of votes cast No effect 4 Approval of IQVIA Holdings Inc.”.

b. Approved under the standard stated in the filing — “Proposal Board Recommendation Vote Required Effect of Absentions and Broker Non-Votes 1 Election of director nominees to serve for the next year and until their successors are elected and qualified FOR each nominee Majority of votes cast No effect 2 Advisory (non-binding) vote to approve our executive compensation (say-on-pay) FOR Not Applicable (1) No effect 3 Ratification of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025 FOR Majority of votes cast No effect 4 Approve an amendment to our Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation FOR Majority of outstanding shares of common stock Abstentions and broker non-votes treated as votes "against" 5 Stockholder proposal, if properly presented AGAINST Not Applicable (1) No effect (1) Given this is an advisory vote, there is no required approval threshold.”.

c. Approved under the standard stated in the filing — “Proposal Board Recommendation Vote Required Effect of Abstentions and Broker Non-Votes Election of six director nominees to one-year terms FOR each nominee Majority of votes cast No effect Advisory (non-binding) vote to approve our executive compensation (say-on-pay) FOR Not Applicable (1) No effect Stockholder proposal, if properly presented AGAINST Not Applicable (1) No effect Ratification of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2024 FOR Majority of votes cast No effect (1) Given this is an advisory vote, there is no required approval threshold.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)275 : 1
CEO total compensation$28,128,245
Median employee compensation$102,424
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
John M. Leonard, M.DIndependent · Lead Independent Director · Audit · Leadership Development and Compensation · Nominating and Governance$178,125$239,883$0$0$0$418,008
James A. FasanoIndependent · Audit (Chair) · Leadership Development and Compensation150,625239,883000390,508
Carol J. BurtIndependent · Leadership Development and Compensation (Chair) · Audit145,625239,883000385,508
Colleen A. GogginsIndependent · Nominating and Governance (Chair) · Audit143,125239,883000383,008
John G. DanhaklIndependent · Leadership Development and Compensation · Nominating and Governance123,125239,883000363,008
Sheila A. StampsIndependent · Audit118,125239,883000358,008
Leslie Wims MorrisIndependent · Nominating and Governance113,125239,883000353,008
William G. Kaelin Jr., M.DIndependent · Newly elected28,125000028,125
John P. ConnaughtonIndependent · Leadership Development and Compensation · Not standing for re-election · Departed during FY27,500000027,500
Todd B. SisitskyIndependent · Leadership Development and Compensation · Nominating and Governance000000
Ari BousbibEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer$112,500
Annual equity retainer$240,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)—
Stock ownership guideline5x annual cash retainer
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$1,027,500
Equity awards (grant-date value)$1,679,181
All other compensation$0
Total cost of the board$2,706,681

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies IQVIA HOLDINGS INC. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including IQVIA HOLDINGS INC..

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Thermo Fisher Scientific, Inc.2025Marc Casper$1,785,534$65,730,211$7,951,377$3,742,123$79,923,350
2International Business Machines Corp.2025Arvind Krishna1,500,00023,988,5866,606,3125,250,00037,989,685
3Eli Lilly & Co.2025David Ricks1,700,00023,325,00006,485,50036,698,337
4AbbVie Inc.2025Robert Michael1,700,00013,268,4563,199,1545,200,00032,530,984
5Accenture plc2025Julie Sweet1,550,00022,876,23204,500,00029,641,903
6IQVIA HOLDINGS INC.2025Ari Bousbib1,800,00015,749,9574,528,3174,966,12728,128,245
7Pfizer Inc.2025Albert Bourla1,800,0009,442,7058,998,1415,400,00027,585,301
8Amgen Inc.2025Robert Bradway1,925,40912,599,5895,399,9963,907,00024,693,120
9Danaher Corporation2025Rainer Blair1,400,0009,292,3708,386,6574,194,40023,795,280
10Biogen Inc.2025Christopher Viehbacher1,727,88518,368,87503,190,87523,646,004
11Cognizant Technology Solutions Corp.2025Ravi Kumar1,300,00015,824,49804,394,00021,532,448
12Vertex Pharmaceuticals Inc.2025Reshma Kewalramani1,600,00015,002,27004,118,64021,144,261
13Merck & Co., Inc.2025Robert Davis1,645,30212,102,8383,380,0042,326,50020,797,845
14Gartner, Inc.2025Eugene Hall985,18511,619,4774,979,9321,483,65519,226,580
15Zoetis Inc.2025Kristin Peck1,350,00010,218,5833,406,2292,187,00019,046,509
16Agilent Technologies, Inc.2025Padraig McDonnell1,141,3458,169,8502,017,7591,436,80912,827,236
17Regeneron Pharmaceuticals, Inc.2025Leonard Schleifer1,979,922——3,682,6557,280,549
18Avantor, Inc.2025Emmanuel Ligner379,2972,499,9902,499,998330,0385,895,624
19Pharmaceuticals2025Paula Ragan420,1701,081,575002,640,569

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
IQVIA HOLDINGS INC.not disclosedPSU 75 · Options 25YesMeridian Compensation Partners, LLC
AbbVie Inc.not disclosedPSU 40 · PRSU 40 · Option 20Yes — Relative TSRSemler Brossy
Accenture plcnot disclosednot disclosedNoPay Governance LLC
Agilent Technologies, Inc.not disclosedPSU 60 · Options 20 · RSU 20NoSemler Brossy
Amgen Inc.136.0%PSU 50 · Options 30 · RSU 20Yes — relative TSRFrederic W. Cook & Co., Inc. (FW Cook)
Avantor, Inc.56.9%PSU 50 · Options 25 · RSU 25Yes — TSR Relative to Comparator GroupFW Cook
Biogen Inc.127%PSU 60 · RSU 40YesPay Governance
Cognizant Technology Solutions Corp.169%PSU 60 · RSU 40Yes — total shareholder return (TSR)Pay Governance
Danaher Corporationnot disclosedOptions 50 · RSU 50Yes — Relative TSRFW Cook
Eli Lilly & Co.218%PSU 100NoFW Cook
Gartner, Inc.119.6%PSU 70 · Options 30NoExequity
International Business Machines Corp.150%not disclosedYes — Relative Total Shareholder Return (rTSR)Semler Brossy
Merck & Co., Inc.94%PSU 60 · RSU 20 · Options 20Yes — Relative Total Shareholder Return (R-TSR)FW Cook
Pfizer Inc.150%PSU 50 · MSU 50Yes — relative TSR as compared to the NYSE Arca Pharmaceutical Index (DRG Index or DRG)Meridian Compensation Partners, LLC
Pharmaceuticalsnot disclosednot disclosednot disclosednot disclosed
Regeneron Pharmaceuticals, Inc.155%Options 60 · RSU 40not disclosedPay Governance LLC
Thermo Fisher Scientific, Inc.99.8%PSU 50 · Options 50Yes — Relative TSRPearl Meyer
Vertex Pharmaceuticals Inc.not disclosedPSU 55 · RSU 45Nonot disclosed
Zoetis Inc.108%PSU 50 · Options 25 · RSU 25Yes — Relative TSRPearl Meyer

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at IQVIA HOLDINGS INC. in fiscal 2025?
As disclosed, Ari Bousbib (Chairman and Chief Executive Officer) was the highest-paid executive at IQVIA HOLDINGS INC. in fiscal 2025, with total compensation of $28,128,245.
How does IQVIA HOLDINGS INC.'s chief executive pay compare to its disclosed peer group?
As disclosed, Ari Bousbib's total compensation ranked at the 72nd percentile of IQVIA HOLDINGS INC.'s disclosed peer group.
What is IQVIA HOLDINGS INC.'s CEO-to-median employee pay ratio?
As disclosed, IQVIA HOLDINGS INC.'s CEO-to-median employee pay ratio was 275:1.
How did shareholders vote on IQVIA HOLDINGS INC.'s executive compensation?
As disclosed, 80.11% of shareholders supported IQVIA HOLDINGS INC.'s executive compensation in the latest say-on-pay vote.
How much does IQVIA HOLDINGS INC. spend in total on board compensation for fiscal 2025?
As disclosed, IQVIA HOLDINGS INC. reported total board compensation of $2,706,681 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Ari BousbibDEF 14A2026-02-270001628280-26-012892Section “2025 Summary Compensation Table”. As printed: 28,128,245. Filing ↗machine: t232 · r4 · c10 · span 1613956–1613966
2Section 01, Ronald BruehlmanDEF 14A2026-02-270001628280-26-012892Section “Summary Compensation Table” · page 86. As printed: 11,444,200. Filing ↗machine: t232 · r8 · c9 · span 1623347–1623357
3Section 01, Alistair GrenfellDEF 14A2026-02-270001628280-26-012892Section “2025 Summary Compensation Table”. As printed: 9,704,506. Filing ↗machine: t232 · r16 · c10 · span 1642619–1642628
4Section 01, W. Richard Staub IIIDEF 14A2026-02-270001628280-26-012892Section “2025 Summary Compensation Table”. As printed: 8,828,979. Filing ↗machine: t232 · span 1632726–1632735
5Section 01, Eric SherbetDEF 14A2026-02-270001628280-26-012892Section “Summary Compensation Table” · page 86. As printed: 5,500,798. Filing ↗machine: t232 · r18 · c9 · span 1646243–1646252
6Section 03, W. Richard Staub III DEF 14A2026-02-270001628280-26-012892Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t232 · r12 · c4 · span 1631123–1631132
7Section 03, Alistair Grenfell DEF 14A2026-02-270001628280-26-012892Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t236 · r20 · c7 · span 1717762–1717768
8Section 03, Ari Bousbib DEF 14A2026-02-270001628280-26-012892Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t236 · r8 · c7 · span 1683851–1683857
9Section 03, Ari Bousbib DEF 14A2026-02-270001628280-26-012892Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t236 · r8 · c8 · span 1684134–1684140
10Section 03, Ronald Bruehlman DEF 14A2026-02-270001628280-26-012892Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t236 · r12 · c8 · span 1695438–1695444
11Section 03, W. Richard Staub III DEF 14A2026-02-270001628280-26-012892Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t232 · r12 · c5 · span 1631445–1631454
12Section 03, Alistair Grenfell DEF 14A2026-02-270001628280-26-012892Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t219 · r6 · c4 · span 1529205–1529214
13Section 03, Eric Sherbet DEF 14A2026-02-270001628280-26-012892Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t236 · r24 · c7 · span 1729060–1729065
14Section 03, Eric Sherbet DEF 14A2026-02-270001628280-26-012892Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t219 · r7 · c4 · span 1530429–1530436
15Section 03, Alistair Grenfell PSUDEF 14A2026-02-270001628280-26-012892Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t236 · r20 · c8 · span 1718045–1718051
16Section 03, Ronald Bruehlman DEF 14A2026-02-270001628280-26-012892Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t236 · r12 · c7 · span 1695155–1695161
17Section 07, pay ratioDEF 14A2026-02-270001628280-26-012892Section “CEO Pay Ratio”. As printed: 275 : 1. Filing ↗machine: span 2159316–2159321
18Section 08, John M. Leonard, M.DDEF 14A2026-02-270001628280-26-012892Section “Director Compensation”. As printed: 418,008. Filing ↗machine: t73 · r9 · c6 · span 582038–582224
19Section 08, James A. FasanoDEF 14A2026-02-270001628280-26-012892Section “Director Compensation”. As printed: 390,508. Filing ↗machine: t73 · r6 · c6 · span 576295–576481
20Section 08, Carol J. BurtDEF 14A2026-02-270001628280-26-012892Section “Director Compensation”. As printed: 385,508. Filing ↗machine: t73 · r3 · c6 · span 570331–570517
21Section 08, Colleen A. GogginsDEF 14A2026-02-270001628280-26-012892Section “Director Compensation”. As printed: 383,008. Filing ↗machine: t73 · r7 · c6 · span 578265–578451
22Section 08, John G. DanhaklDEF 14A2026-02-270001628280-26-012892Section “Director Compensation”. As printed: 363,008. Filing ↗machine: t73 · r5 · c6 · span 574325–574511
23Section 08, Sheila A. StampsDEF 14A2026-02-270001628280-26-012892Section “Director Compensation”. As printed: 358,008. Filing ↗machine: t73 · r12 · c6 · span 588168–588354
24Section 08, Leslie Wims MorrisDEF 14A2026-02-270001628280-26-012892Section “Director Compensation”. As printed: 353,008. Filing ↗machine: t73 · r10 · c6 · span 584008–584194
25Section 08, William G. Kaelin Jr., M.DDEF 14A2026-02-270001628280-26-012892Section “Director Compensation”. As printed: 28,125. Filing ↗machine: t73 · r8 · c2 · span 579328–579513
26Section 08, John P. ConnaughtonDEF 14A2026-02-270001628280-26-012892Section “Director Compensation”. As printed: 27,500. Filing ↗machine: t73 · r4 · c2 · span 571444–571629
27Section 08, Todd B. SisitskyDEF 14A2026-02-270001628280-26-012892Section “Director Compensation”. As printed: 0. Filing ↗
28Section 08, Ari BousbibDEF 14A2026-02-270001628280-26-012892Section “Director Compensation”. As printed: 0. Filing ↗
29Section 02, Carol J. Burt 2026-04-23Form 42026-04-270001628280-26-027596Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, John G. Danhakl 2026-04-23Form 42026-04-270001628280-26-027604Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, John M. Leonard 2026-04-23Form 42026-04-270001628280-26-027609Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Morris Leslie Wims 2026-04-23Form 42026-04-270001628280-26-027611Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Sheila A. Stamps 2026-04-23Form 42026-04-270001628280-26-027612Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Colleen A. Goggins 2026-04-23Form 42026-04-270001628280-26-027607Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, James A. Fasano 2026-04-23Form 42026-04-270001628280-26-027605Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, William G. Kaelin Jr 2026-04-23Form 42026-04-270001628280-26-027610Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, John G. Danhakl 2026-05-07Form 42026-05-110001628280-26-033650Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, James A. Fasano 2026-05-07Form 42026-05-110001628280-26-033653Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Colleen A. Goggins 2026-05-07Form 42026-05-110001628280-26-033654Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Morris Leslie Wims 2026-05-07Form 42026-05-110001628280-26-033655Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, John G. Danhakl 2026-07-14Form 42026-07-160001628280-26-048501Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, James A. Fasano 2026-07-14Form 42026-07-160001628280-26-048502Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Colleen A. Goggins 2026-07-14Form 42026-07-160001628280-26-048503Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Morris Leslie Wims 2026-07-14Form 42026-07-160001628280-26-048504Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Ari Bousbib 2026-07-29Form 42026-07-310001628280-26-051449Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Ari Bousbib 2026-07-29Form 42026-07-310001628280-26-051449Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Ari Bousbib 2026-07-29Form 42026-07-310001628280-26-051449Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Ari Bousbib 2026-07-29Form 42026-07-310001628280-26-051449Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Ari Bousbib 2026-07-29Form 42026-07-310001628280-26-051449Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Ari Bousbib 2026-07-29Form 42026-07-310001628280-26-051449Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Eric Sherbet 2026-07-29Form 42026-07-310001628280-26-051451Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Ari Bousbib 2026-07-29Form 42026-07-310001628280-26-051449Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Ari Bousbib 2026-07-29Form 42026-07-310001628280-26-051449Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Keriann Cherofsky 2026-07-29Form 42026-07-310001628280-26-051450Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Bhavik Patel 2026-07-31Form 42026-08-040001628280-26-052701Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, W. Richard Staub III 2026-08-03Form 42026-08-040001628280-26-052703Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, James G. Berkshire 2026-09-02Form 42026-09-040001628280-26-060755Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, James G. Berkshire 2026-09-02Form 42026-09-040001628280-26-060755Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, James G. Berkshire 2026-09-02Form 42026-09-040001628280-26-060755Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, James G. Berkshire 2026-09-02Form 42026-09-040001628280-26-060755Insider equity transaction reported since the proxy statement. Filing ↗
61Section 06, 2026 voteForm 8-K2026-04-230001193125-26-173771Item 5.07 · say-on-pay result. As reported: 80.11% (votes for as printed: 118,398,355). Filing ↗
62Section 06, 2025 voteForm 8-K2025-04-240001193125-25-093687Item 5.07 · say-on-pay result. As reported: 82.74% (votes for as printed: 125,637,769). Filing ↗
63Section 06, 2024 voteForm 8-K2024-04-170001193125-24-098516Item 5.07 · say-on-pay result. As reported: 83.72% (votes for as printed: 134,057,263). Filing ↗
64Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
65Section 09b board cost (computed)Computed——Cash 1,027,500 + equity 1,679,181 + all other 0 = 2,706,681, summed across the director compensation table rows.machine: formula: Σ = 2,706,681
66Thermo Fisher Scientific, Inc., Section 10b CEO totalDEF 14A2026-04-070001193125-26-144585CEO total compensation as printed in Thermo Fisher Scientific, Inc.'s own proxy. As printed: 79,923,350. Filing ↗machine: span 973487–973497
67International Business Machines Corp., Section 10b CEO totalDEF 14A2026-03-100000051143-26-000025CEO total compensation as printed in International Business Machines Corp.'s own proxy. As printed: 37,989,685. Filing ↗machine: r11 · c51 · span 1119293–1119303
68Eli Lilly & Co., Section 10b CEO totalDEF 14A2026-03-200000059478-26-000029CEO total compensation as printed in Eli Lilly & Co.'s own proxy. As printed: 36,698,337. Filing ↗machine: t92 · r2 · c20 · span 925013–925024
69AbbVie Inc., Section 10b CEO totalDEF 14A2026-03-230001104659-26-033387CEO total compensation as printed in AbbVie Inc.'s own proxy. As printed: 32,530,984. Filing ↗
70Accenture plc, Section 10b CEO totalDEF 14A2025-12-120001308179-25-000651CEO total compensation as printed in Accenture plc's own proxy. As printed: 29,641,903. Filing ↗machine: t149 · r4 · c23 · span 1117150–1117161
71IQVIA HOLDINGS INC. (subject), Section 10b CEO totalDEF 14A2026-02-270001628280-26-012892CEO total compensation as printed in IQVIA HOLDINGS INC.'s own proxy. As printed: 28,128,245. Filing ↗machine: t232 · r4 · c10 · span 1613956–1613966
72Pfizer Inc., Section 10b CEO totalDEF 14A2026-03-120000078003-26-000033CEO total compensation as printed in Pfizer Inc.'s own proxy. As printed: 27,585,301. Filing ↗machine: t242 · r3 · c12 · span 1506825–1506835
73Amgen Inc., Section 10b CEO totalDEF 14A2026-04-070001193125-26-145588CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166
74Danaher Corporation, Section 10b CEO totalDEF 14A2026-03-250000313616-26-000101CEO total compensation as printed in Danaher Corporation's own proxy. As printed: 23,795,280. Filing ↗machine: t122 · r2 · c21 · span 1070180–1070190
75Biogen Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-187303CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391
76Cognizant Technology Solutions Corp., Section 10b CEO totalDEF 14A2026-04-170001308179-26-000290CEO total compensation as printed in Cognizant Technology Solutions Corp.'s own proxy. As printed: 21,532,448. Filing ↗machine: span 1005982–1005992
77Vertex Pharmaceuticals Inc., Section 10b CEO totalDEF 14A2026-04-020000875320-26-000153CEO total compensation as printed in Vertex Pharmaceuticals Inc.'s own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809
78Merck & Co., Inc., Section 10b CEO totalDEF 14A2026-04-080001193125-26-147704CEO total compensation as printed in Merck & Co., Inc.'s own proxy. As printed: 20,797,845. Filing ↗machine: span 1371012–1371022
79Gartner, Inc., Section 10b CEO totalDEF 14A2026-04-150000749251-26-000159CEO total compensation as printed in Gartner, Inc.'s own proxy. As printed: 19,226,580. Filing ↗machine: r2 · c21 · span 686397–686407
80Zoetis Inc., Section 10b CEO totalDEF 14A2026-04-080001555280-26-000015CEO total compensation as printed in Zoetis Inc.'s own proxy. As printed: 19,046,509. Filing ↗machine: r3 · c24 · span 1448788–1448798
81Agilent Technologies, Inc., Section 10b CEO totalDEF 14A2026-02-060001193125-26-040286CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992
82Regeneron Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-240001308179-26-000340CEO total compensation as printed in Regeneron Pharmaceuticals, Inc.'s own proxy. As printed: 7,280,549. Filing ↗machine: r3 · c10 · span 3335980–3335989
83Avantor, Inc., Section 10b CEO totalDEF 14A2026-03-270001628280-26-021572CEO total compensation as printed in Avantor, Inc.'s own proxy. As printed: 5,895,624. Filing ↗machine: r3 · c9 · span 2130032–2130041
84Pharmaceuticals, Section 10b CEO totalDEF 14A2026-03-200001501697-26-000031CEO total compensation as printed in Pharmaceuticals's own proxy. As printed: 2,640,569. Filing ↗machine: span 520865–520874
85Section 10a, Agilent Technologies, Inc. reciprocityDEF 14A—0001193125-26-040286Agilent Technologies, Inc. names IQVIA HOLDINGS INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
86Section 10a, Regeneron Pharmaceuticals, Inc. reciprocityDEF 14A—0001308179-26-000340Regeneron Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include IQVIA HOLDINGS INC.. Filing ↗
87Section 10a, AbbVie Inc. reciprocityDEF 14A—0001104659-26-033387AbbVie Inc.'s most recent proxy was read; its disclosed peer group does not include IQVIA HOLDINGS INC.. Filing ↗
88Section 10a, Vertex Pharmaceuticals Inc. reciprocityDEF 14A—0000875320-26-000153Vertex Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include IQVIA HOLDINGS INC.. Filing ↗
89Section 10a, Accenture plc reciprocityDEF 14A—0001308179-25-000651Accenture plc's most recent proxy was read; its disclosed peer group does not include IQVIA HOLDINGS INC.. Filing ↗
90Section 10a, Cognizant Technology Solutions Corp. reciprocityDEF 14A—0001308179-26-000290Cognizant Technology Solutions Corp.'s most recent proxy was read; its disclosed peer group does not include IQVIA HOLDINGS INC.. Filing ↗
91Section 10a, Gartner, Inc. reciprocityDEF 14A—0000749251-26-000159Gartner, Inc.'s most recent proxy was read; its disclosed peer group does not include IQVIA HOLDINGS INC.. Filing ↗
92Section 10a, International Business Machines Corp. reciprocityDEF 14A—0000051143-26-000025International Business Machines Corp.'s most recent proxy was read; its disclosed peer group does not include IQVIA HOLDINGS INC.. Filing ↗
93Section 10a, Danaher Corporation reciprocityDEF 14A—0000313616-26-000101Danaher Corporation names IQVIA HOLDINGS INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
94Section 10a, Merck & Co., Inc. reciprocityDEF 14A—0001193125-26-147704Merck & Co., Inc.'s most recent proxy was read; its disclosed peer group does not include IQVIA HOLDINGS INC.. Filing ↗
95Section 10a, Pfizer Inc. reciprocityDEF 14A—0000078003-26-000033Pfizer Inc.'s most recent proxy was read; its disclosed peer group does not include IQVIA HOLDINGS INC.. Filing ↗
96Section 10a, Zoetis Inc. reciprocityDEF 14A—0001555280-26-000015Zoetis Inc. names IQVIA HOLDINGS INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
97Section 10a, Eli Lilly & Co. reciprocityDEF 14A—0000059478-26-000029Eli Lilly & Co.'s most recent proxy was read; its disclosed peer group does not include IQVIA HOLDINGS INC.. Filing ↗
98Section 10a, Avantor, Inc. reciprocityDEF 14A—0001628280-26-021572Avantor, Inc. names IQVIA HOLDINGS INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
99Section 10a, Amgen Inc. reciprocityDEF 14A—0001193125-26-145588Amgen Inc.'s most recent proxy was read; its disclosed peer group does not include IQVIA HOLDINGS INC.. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the IQVIA HOLDINGS INC. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
IQV Peer Teardown Report